Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
, 96 (24), e7116

Incidence, Prevalence, and Natural History of Primary Sclerosing Cholangitis in the United Kingdom

Affiliations
Observational Study

Incidence, Prevalence, and Natural History of Primary Sclerosing Cholangitis in the United Kingdom

Huifang Liang et al. Medicine (Baltimore).

Abstract

Primary sclerosing cholangitis (PSC) is a rare obliterative fibrotic condition of the bile ducts. We assessed PSC epidemiology and natural history within the UK Clinical Practice Research Datalink (CPRD).Incidence and natural history of PSC were evaluated in a retrospective cohort study using linkage of CPRD, Hospital Episode Statistics, and Office for National Statistics data. Data from age, sex, and general practice-matched population controls provided a context for the incident PSC patients. Liver disease other than PSC was defined as autoimmune hepatitis, hepatitis, hepatomegaly, liver failure, cirrhosis, portal hypertension, cholangiocarcinoma, or hepatobiliary cancer.The age-standardized incidence of PSC was 0.68 (95% confidence interval [CI] 0.45-0.99) per 100,000 person-years and the age-standardized prevalence was 5.58 (95% CI 4.82-7.35) per 100,000 during 1998 to 2014. In all, 250 incident PSC patients met the inclusion criteria and each was matched with 5 controls (mean age 54 ± 18 years, men 63.2%). A higher percentage of PSC patients had a history of inflammatory bowel disease (54% vs 2%) and liver disease other than PSC (22% vs 1%) than controls (standardized differenceweighted >0.1). During a median follow-up of 5 years, PSC patients were more likely to develop adverse health outcomes. The mortality rate per 1000 person-years was 3-fold higher in PSC than population controls (49.5 vs 16.1; incidence rate ratio 3.1, 95% CI 2.2-4.2).The incidence and prevalence of PSC observed in the UK CPRD were either comparable with or higher than previous studies. Compared with the general population, PSC patients had worse health outcomes including PSC disease progression, complications, and higher mortality.

Conflict of interest statement

Conflicts of interest: H.L., S.M., J.S., T.L., and P.D. were employees of Takeda Pharmaceuticals at the time of the study and may receive stocks and/or stock options from Takeda. No other conflicts of interest were reported by the authors.

Figures

Figure 1
Figure 1
(A) Age and sex-standardized incidence of PSC in the UK in 1998 to 2014. (B) Age and sex-standardized prevalence of PSC in the UK in 1998 to 2014. PSC = primary sclerosing cholangitis.
Figure 2
Figure 2
Methodology to identify incident PSC patients and matched general population in 1998 to 2014. Note: Two inclusion criteria, the index date was before the censor date and 1 year of registration with a GP before the index date, for non-PSC controls were applied in matching. PSC = primary sclerosing cholangitis.
Figure 3
Figure 3
Kaplan–Meier survival curve of incident PSC patients and matched general population. PSC = primary sclerosing cholangitis.

Similar articles

See all similar articles

Cited by 8 PubMed Central articles

See all "Cited by" articles

References

    1. Tanaka A, Takikawa H. Geoepidemiology of primary sclerosing cholangitis: a critical review. J Autoimmun 2013;46:35–40. - PubMed
    1. Sano H, Nakazawa T, Ando T, et al. Clinical characteristics of inflammatory bowel disease associated with primary sclerosing cholangitis. J Hepatobiliary Pancreat Sci 2011;18:154–61. - PubMed
    1. Okada H, Mizuno M, Yamamoto K, et al. Primary sclerosing cholangitis in Japanese patients: association with inflammatory bowel disease. Acta Med Okayama 1996;50:227–35. - PubMed
    1. Boonstra K, van Erpecum KJ, van Nieuwkerk KM, et al. Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease. Inflamm Bowel Dis 2012;18:2270–6. - PubMed
    1. de Valle MB, Bjornsson E, Lindkvist B. Mortality and cancer risk related to primary sclerosing cholangitis in a Swedish population-based cohort. Liver Int 2012;32:441–8. - PubMed

Publication types

Feedback